Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
Follow-Up Questions
Aditxt Inc의 CEO는 누구입니까?
Mr. Amro Albanna은 2017부터 회사에 합류한 Aditxt Inc의 Chairman of the Board입니다.
ADTX 주식의 가격 성능은 어떻습니까?
ADTX의 현재 가격은 $0.2439이며, 전 거래일에 increased 13.39% 하였습니다.
Aditxt Inc의 주요 사업 주제나 업종은 무엇입니까?
Aditxt Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Aditxt Inc의 시가총액은 얼마입니까?
Aditxt Inc의 현재 시가총액은 $1.2M입니다
Aditxt Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Aditxt Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 4명의 매수, 2명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
